ALGS Financials Aligos Therapeutics, Inc.
7 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $2M | -$24M | 0.0% | -4024.9% | -45.2% | -27.3% | — | — | $18M |
| 2024 | $4M | -$131M | 0.0% | -2469.0% | 452.9% | -187.2% | -$81M | — | $37M |
| 2023 | $6M | -$88M | 0.0% | -1423.5% | -95.2% | -57.9% | -$79M | — | $136M |
| 2022 | $0 | -$96M | — | — | -92.4% | -65.5% | -$80M | — | $81M |
| 2021 | $0 | -$128M | — | — | -69.5% | -54.5% | -$117M | — | $187M |
| 2020 | $0 | -$109M | — | — | -49.3% | -40.9% | -$76M | — | $220M |
| 2019 | — | -$52M | — | — | 80.5% | -35.7% | -$50M | — | $70M |
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$2M | — | — | -4.7% | -2.3% | — | — | $30M |
| Mar '26 | $3M | -$23M | 0.0% | -951.6% | -72.5% | -35.7% | — | — | $30M |
| Dec '25 | $169000 | -$20M | 0.0% | -12907.7% | -37.1% | -22.5% | — | — | $18M |
| Sep '25 | $741000 | -$32M | 0.0% | -3827.4% | -43.9% | -28.7% | — | — | $42M |
| Jun '25 | $965000 | -$16M | 0.0% | -1924.0% | -15.6% | -11.8% | — | — | $19M |
| Mar '25 | $311000 | $43M | 0.0% | -6187.5% | 37.0% | 28.6% | — | — | $74M |
| Dec '24 | $606000 | -$82M | 0.0% | -3393.2% | 283.5% | -117.2% | — | — | $37M |
| Sep '24 | $1M | -$19M | 0.0% | -1610.5% | -38.4% | -21.8% | — | — | $35M |
| Jun '24 | $1M | $5M | 0.0% | -2489.5% | 7.5% | 4.7% | — | — | $45M |
| Mar '24 | $694000 | -$35M | 0.0% | -3176.7% | -58.3% | -27.3% | — | — | $24M |
| Dec '23 | $672000 | -$28M | 0.0% | -3868.6% | -30.3% | -18.4% | — | — | $136M |
| Sep '23 | $1M | -$18M | 0.0% | -1757.7% | -32.9% | -21.0% | — | — | $70M |
| Jun '23 | $4M | -$19M | 0.0% | -445.8% | -27.0% | -17.7% | — | — | $91M |
| Mar '23 | $140000 | -$23M | 0.0% | -17084.3% | -27.1% | -18.9% | -$22M | — | $79M |
| Dec '22 | — | -$22M | — | — | -21.1% | -14.9% | -$17M | — | $81M |
| Sep '22 | $0 | -$19M | — | — | -15.3% | -11.3% | -$17M | — | $86M |
| Jun '22 | $0 | -$20M | — | — | -14.5% | -10.9% | -$25M | — | $71M |
| Mar '22 | — | -$36M | — | — | -23.3% | -16.9% | -$21M | — | $105M |
| Dec '21 | — | -$38M | — | — | -20.4% | -16.0% | -$38M | — | $187M |
| Sep '21 | — | -$33M | — | — | -15.3% | -12.6% | -$25M | — | $240M |
Valuation over time
How the market has priced ALGS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 17.3× (Jan '24) to 13.4× (Nov '26).
Frequently asked questions
Is ALGS growing its revenue and profit?
See the revenue and net-income charts above for Aligos Therapeutics, Inc.'s multi-year trend.
How much debt does ALGS have?
As of FY2025, Aligos Therapeutics, Inc. reported — of total debt against $18M of cash.
What is ALGS's profit margin?
In FY2025, gross margin was —, operating margin -4024.9%, and net margin -1106.7%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.